Squalene Market By Source (Plant-derived Squalene, Marine-origin Squalene, Biosynthetic Squalene); By Application (Cosmetics & Personal Care, Pharmaceuticals, Nutraceuticals & Functional Foods, Industrial Applications); By End User (Cosmetics Brands, Pharmaceutical Companies, Nutraceutical Manufacturers, Industrial Chemical Companies); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Squalene Market: Skincare Remains the Core Demand Base, While Hair Care Broadens Formulation Use – (Updated On: 3rd-Sep-2026)

The Global Squalene Market was valued at USD 2.05 billion in 2025 and is projected to reach USD 3.62 billion by 2032, expanding at an 8.4% CAGR. In personal care, commercial demand is increasingly realized through squalane, the more oxidation-stable derivative of squalene, particularly in leave-on moisturizing formulations.

 

Skincare shows the strongest application depth. U.S. EPA ChemExpo currently lists squalane across 913 facial cleansing and moisturizing formulations, including 825 face creams/moisturizers, alongside 428 general moisturizing and hand/body lotion formulations. This concentration indicates that facial hydration and barrier-support products remain the primary route through which squalene-derived ingredients reach consumers.

 

FDA formulation-use data reviewed by the Cosmetic Ingredient Review provide a similar signal: squalane appeared in 2,785 formulations in 2019, of which 2,608 were leave-on products and 2,447 involved dermal contact. Squalene itself appeared in 527 formulations, including 453 dermal-contact uses.

 

Hair care is smaller but increasingly relevant. Squalane use in non-coloring hair products increased from 17 formulations in 2001 to 69 in 2019, while EPA ChemExpo identifies 56 hair styling/care formulations, including 22 conditioners and 6 shampoos containing squalane.

 

The demand profile is therefore clearly skincare-led, but expanding into conditioners, styling products and shampoos as formulators extend squalane’s emollient role from skin barrier care into hair-conditioning applications.

 

Squalene Market Key Report Takeaways Across Major Segments

• Plant-derived squalene holds the leading position by source, capturing 48.0% of market revenue and advancing at a 9.2% CAGR. Biosynthetic squalene, although smaller at 15.0%, is expanding most rapidly, with growth projected at 12.4% CAGR.

• Cosmetics & Personal Care represents the largest application category, accounting for 44.0% of the market and growing at an 8.0% CAGR. Nutraceuticals & Functional Foods show the strongest application momentum, reaching a 10.5% CAGR from a 22.0% share.

• Cosmetics Brands constitute the primary end-user segment, contributing 40.0% of revenue and recording an 8.0% CAGR. Nutraceutical Manufacturers account for 24.0% and are expected to post the highest end-user growth rate at 10.2% CAGR.

• North America generated the largest regional contribution in 2025, with a 34.0% share and an 8.0% CAGR. Asia Pacific follows at 28.0% but leads regional expansion, growing at a projected 10.3% CAGR.

 

Squalene Market Source Analysis Shows Plant Leadership and Faster Biosynthetic Adoption

Plant-derived squalene remained the leading source in 2025, generating USD 0.984 billion and capturing 48.0% of total market revenue. The segment is forecast to advance at a 9.2% CAGR, supported by the availability of olive-processing residues, amaranth oil and other botanical feedstocks. With the EU responsible for approximately 67% of global olive-oil production, the region offers a sizeable raw-material base for squalene recovery. Evonik's amaranth-derived PhytoSquene illustrates the pharmaceutical opportunity, whereas SOPHIM focuses on extracting squalene from olive-derived streams and transforming it into cosmetic emollients.

Marine-origin squalene contributed USD 0.759 billion in 2025, corresponding to a 37.0% market share, but is expected to grow at a more modest 5.5% CAGR. Its continued presence is linked to the high concentration of squalene in shark liver oil and to purification infrastructure that already supports supplement producers and specialty-ingredient buyers. Nissei Marine and Champion remain active across marine-sourced squalene supply, including bulk ingredients, supplements and OEM programs. Nevertheless, rising biodiversity concerns and broader CITES oversight are encouraging customers to investigate plant-based and fermentation-derived substitutes wherever technical specifications and regulatory approvals allow.

Although biosynthetic squalene represented only 15.0% of the market in 2025, worth USD 0.308 billion, it is projected to record the strongest growth at a 12.4% CAGR. Microbial fermentation enables tighter control over raw-material provenance and production consistency while limiting exposure to fisheries and fluctuating agricultural by-product supplies. Amyris and Croda have advanced this route by pairing precision fermentation with pharmaceutical-grade purification for vaccine and drug-delivery applications. Amyris also lists commercial squalene production among the applications supported by its broader fermentation platform.

 

Squalene Market Application and End-User Analysis Reflects Beauty Scale and Higher-Value Healthcare Demand

Cosmetics & Personal Care remains the leading application, generating USD 0.902 billion in 2025 and representing 44.0% of total market revenue. The segment is forecast to advance at an 8.0% CAGR, supported by squalene's emollient properties and its conversion into oxidation-resistant cosmetic squalane. Henry Lamotte Oils, for instance, promotes the ingredient for skin-feel enhancement, hair-care products and pigment dispersion. Future gains will increasingly favor formulations that pair strong sensory benefits with verifiable botanical or biotechnology-based sourcing.

Pharmaceutical use contributes USD 0.533 billion, equivalent to 26.0% of the market, and is expected to rise at an 8.2% CAGR. Although its volume is below that of personal care, the category demands more rigorous supplier qualification, including control of impurities, validated purity and dependable batch availability. Seqirus' FLUAD provides a notable example, as its MF59 adjuvant uses a squalene-based oil-in-water emulsion. Continued use of MF59 in licensed influenza vaccines sustains demand for tightly specified pharmaceutical-grade material.

Nutraceuticals & Functional Foods generate USD 0.451 billion and capture 22.0% of market revenue. With a projected 10.5% CAGR, this category is expanding faster than any other application area. Squalene is appearing in softgels, capsules and fortified-food concepts, although manufacturers must manage its susceptibility to oxidation. Nissei Marine's supplement portfolio demonstrates existing commercial activity, while research into encapsulation and olive-processing residues could support additional functional-food formats.

Industrial Applications comprise a smaller USD 0.164 billion opportunity, corresponding to an 8.0% share, and are projected to grow at 6.5% annually. Rather than serving mass-volume chemistry, this segment relies on squalene for specialized synthesis, analytical procedures and research uses where its molecular profile warrants a premium. FUJIFILM Wako and Tokyo Chemical Industry supply laboratory and research grades, highlighting the recurring requirements of chemical, analytical and R&D customers.

Among end users, Cosmetics Brands lead with USD 0.820 billion in 2025 revenue, a 40.0% share and an 8.0% CAGR. These companies are exerting greater influence over upstream sourcing decisions, particularly around ingredient origin. L'Oréal identifies olive- and sugarcane-derived squalane in its ingredient strategy, while The Ordinary markets plant-derived sugarcane squalane. Because squalane is hydrogenated squalene, these examples do not represent direct squalene sales, but they do signal rising downstream preference for renewable feedstocks and associated production technologies.

Pharmaceutical Companies account for USD 0.554 billion, or 27.0% of end-user demand, with growth estimated at 8.2% CAGR. Procurement decisions in this group emphasize GMP compliance, regulatory files, reproducibility and supply continuity more heavily than standard cosmetic purchasing. Croda and Evonik are addressing these requirements through non-animal squalene products intended for pharmaceutical and parenteral applications, thereby giving vaccine and drug developers additional qualified sourcing alternatives.

Nutraceutical Manufacturers contribute USD 0.492 billion and hold a 24.0% share, making them the fastest-growing end-user category at a 10.2% CAGR. The market is gradually broadening from conventional marine-oil capsules toward botanical sources and delivery systems designed to improve oxidative protection. At the same time, analytical standardization remains important for product consistency. Suppliers seeking premium nutraceutical contracts therefore need dependable certificates of analysis, validated testing and evidence of formulation stability.

Industrial Chemical Companies represent the balance of the end-user market, with USD 0.185 billion in revenue, a 9.0% share and a 6.3% CAGR. Their consumption is relatively stable because squalene is reserved for selected synthesis routes, reference materials and specialized processing rather than broad commodity production. As a result, purchasing priorities center on grade specifications, technical documentation and reliable availability, while consumer-facing market trends have a more limited effect.

 

Squalene Market Regional Analysis Highlights North American Scale and Asia Pacific Momentum

North America holds the largest regional position, capturing 34.0% of global revenue, or USD 0.697 billion, in 2025, with an 8.0% CAGR through the forecast period. Its strength stems from the combination of a sizable regulated beauty industry and established pharmaceutical applications for squalene-based vaccine adjuvants. By June 2026, the FDA had recorded 16,398 active cosmetic facility registrations and over 1.29 million active product listings. Amyris contributes fermentation-derived ingredient capabilities, while MilliporeSigma supplies several squalene grades for pharmaceutical, analytical and chemical-synthesis uses, giving formulators and laboratories a broad range of sourcing options.

Europe generated USD 0.615 billion in 2025, equivalent to a 30.0% market share, and is projected to expand at a 7.5% CAGR. Regional demand benefits from the €110 billion cosmetics and personal-care sector, as well as close access to the world's leading olive-oil production base. Companies including SOPHIM, Evonik and Croda offer European buyers access to olive-based, amaranth-based and biotechnology-derived sourcing pathways. Strong beauty consumption, pharmaceutical expertise and botanical feedstock availability together reinforce Europe's role in the transition toward non-animal squalene.

Asia Pacific is forecast to be the most dynamic regional market, accounting for 28.0% of 2025 revenue, or USD 0.574 billion, and advancing at a 10.3% CAGR. Expanding cosmetics consumption, rising supplement output and a well-developed specialty-chemicals ecosystem are supporting this momentum. China's cosmetics retail sales among enterprises above the designated size totaled RMB 465.3 billion in 2025, up 5.1% from the previous year, signaling continued growth in downstream formulation activity.

Latin America contributed 5.0% of global revenue in 2025, corresponding to USD 0.103 billion, and is expected to grow at a 7.2% CAGR. The regional market is primarily supplied by imported cosmetic and nutraceutical ingredients, while domestic beauty and wellness manufacturing provides the main demand base. Brazil's fermentation capabilities could gradually strengthen local access to biotechnology-derived specialty ingredients and reduce reliance on imported purified squalene over time.

The Middle East & Africa remains the smallest regional market, with a 3.0% share valued at USD 0.062 billion in 2025 and a projected 6.8% CAGR. Consumption is concentrated in premium skincare, dietary supplements and pharmaceutical distribution, with most purified squalene and squalane sourced from abroad. Although demand is likely to rise steadily, limited regional extraction, refining and biosynthetic infrastructure will continue to restrict the area's contribution to global production.

 

Squalene Market Competitive Landscape Shifts Toward Source Technology and Application Qualification

Competition is becoming less dependent on access to a single raw material and more dependent on the ability to supply defined origin, consistent quality and application-specific documentation. The competitive field includes established marine processors, olive and botanical specialists, precision-fermentation companies, pharmaceutical excipient groups and laboratory chemical suppliers. The broader supplier scan also identifies smaller regional producers and distributors, but the companies below have the clearest current public evidence of relevant commercial portfolios.

Croda International Plc

Croda's portfolio includes Sustainably Sourced Squalene for vaccine and pharmaceutical applications together with a wider adjuvant and drug-delivery platform. Its collaboration with Amyris combines fermentation-based production with Croda's purification, formulation and pharmaceutical-market capabilities.

Evonik Industries AG

Evonik competes through PhytoSquene, its amaranth-derived GMP squalene for parenteral formulations and adjuvants. The product complements Evonik's wider pharmaceutical excipient, lipid, formulation-development and drug-product manufacturing portfolio, giving the company a strong position where buyers require development support alongside raw material.

SOPHIM

SOPHIM specializes in vegetable lipid ingredients and operates around an olive-derived squalene and squalane value chain. Its portfolio includes Phytosqualan Olive, Biophytosebum, Insapolive and related vegetable emollients, allowing it to serve skincare, makeup, hair-care and other personal-care formulators.

Amyris

Amyris supplies precision-fermentation capability for specialty molecules and has commercialized squalene for pharmaceutical use through Croda. Its platform also has a long history in fermentation-derived squalane and other specialty ingredients, giving it manufacturing relevance across beauty and healthcare supply chains.

Merck KGaA / MilliporeSigma

Merck's laboratory and pharmaceutical portfolio spans squalene for synthesis, pharmaceutical secondary standards, European Pharmacopoeia reference material, non-animal material under its EMPROVE portfolio and animal-origin redistilled grades. This breadth addresses R&D, analytical control and regulated manufacturing rather than a single end-use channel.

Nissei Marine Industry

Nissei Marine remains relevant to the traditional marine supply chain through refined shark-liver-derived squalene and the Samemilon supplement portfolio. Its product range extends into dietary supplements, functional-claim foods, quasi-drugs and cosmetics, illustrating how established marine processors can capture value beyond bulk ingredient sales.

A material constraint to the forecast is the cost and technical difficulty of scaling alternative sources while retaining purity. A 2025 ACS Omega study demonstrated strong recovery of squalene from olive pomace but also found that residual impurities could poison hydrogenation catalysts and reduce downstream squalane yield. Fermentation avoids marine-origin risk but still requires efficient bioconversion, purification and customer qualification. The likely outcome through 2032 is therefore coexistence rather than immediate replacement: plant-derived squalene should remain the largest source, biosynthetic material should gain share fastest, and marine material should remain commercially relevant where existing specifications and supply relationships are difficult to change.

 

Analyst Commentary: Shared Fermentation Platforms Could Reshape Squalene Supply Economics

A potentially important shift in the squalene market is the emergence of multi-market biosynthetic production platforms rather than dedicated supply chains for cosmetics, pharmaceuticals and nutraceuticals. Fermentation-derived squalene already represents the fastest-growing source category, and its commercial value may ultimately depend less on sustainability claims than on how efficiently producers can serve several end markets from the same manufacturing base.

The distinction between squalene and squalane is particularly important here. Pharmaceutical customers require highly purified squalene for applications such as vaccine adjuvants, while cosmetics primarily consume hydrogenated squalane. A producer capable of manufacturing consistent fermentation-derived squalene and directing part of that output into cosmetic-grade squalane gains greater flexibility in allocating capacity according to pricing, qualification requirements and customer demand.

Croda and Amyris already provide an early indication of this model by combining precision fermentation with pharmaceutical purification capabilities, while fermentation-derived squalane has an established history in beauty applications.

This could create a competitive advantage that is difficult to replicate through raw-material access alone. Pharmaceutical qualification can support premium pricing and long customer relationships, while cosmetics provide substantially broader formulation volumes. Suppliers able to operate across both markets could therefore achieve better plant utilization and reduce dependence on fluctuations in olive availability or marine sourcing.

The main bottleneck will be purification economics. As the market scales, downstream recovery, impurity removal and hydrogenation efficiency may matter as much as fermentation yield in determining which biosynthetic suppliers can compete profitably.
 

Squalene Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 2.05 Billion
Revenue Forecast in 2032	USD 3.62 Billion
Overall Growth Rate	CAGR of 8.4% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Source, By Application, By End User, By Geography
By Source	Plant-derived Squalene, Marine-origin Squalene, Biosynthetic Squalene
By Application	Cosmetics & Personal Care, Pharmaceuticals, Nutraceuticals & Functional Foods, Industrial Applications
By End User	Cosmetics Brands, Pharmaceutical Companies, Nutraceutical Manufacturers, Industrial Chemical Companies
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Skincare-led demand for squalene-derived squalane in moisturizing and barrier-support formulations; growing adoption of plant-derived and biosynthetic sourcing alternatives; expanding nutraceutical and functional-food applications; increasing pharmaceutical demand for highly purified squalene in vaccine adjuvant and drug-delivery applications
Customization Option	Available upon request